公开(公告)号：US20240360471A1

公开(公告)日：2024-10-31

申请号：US18457258

申请日：2023-08-28

Applicant: EDITAS MEDICINE, INC.

Inventor： Jennifer Leah GORI ,  Luis A. BARRERA

IPC: C12N15/85 ,  C12N5/071 ,  C12N9/22 ,  C12N15/113

CPC classification number: C12N15/85 ,  C12N5/0602 ,  C12N9/22 ,  C12N15/113 ,  C12N2310/20 ,  C12N2310/315 ,  C12N2310/322 ,  C12N2510/00 ,  C12N2800/80

Abstract: Provided herein are CRISPR/Cas-related methods and components for editing a target nucleic acid sequence in a HBG1 and/or HBG2 gene regulatory region, and applications thereof in connection with methods of increasing expression of fetal hemoglobin and treating β-hemoglobinopathies including sickle cell disease and β-thalassemia.

公开(公告)号：US12129492B2

公开(公告)日：2024-10-29

申请号：US17343411

申请日：2021-06-09

Applicant: D. Lansing Taylor ,  Albert Gough ,  Larry Vernetti

Inventor： D. Lansing Taylor ,  Albert Gough ,  Larry Vernetti

IPC: C12N5/071 ,  B01L3/00 ,  C12M1/42 ,  C12M3/06 ,  G01N33/50

CPC classification number: C12N5/0697 ,  B01L3/502715 ,  B01L3/502761 ,  C12M23/16 ,  C12M35/08 ,  C12N5/067 ,  G01N33/5067 ,  G01N33/5082 ,  B01L2300/0636 ,  C12N2502/11 ,  C12N2502/14 ,  C12N2502/28 ,  C12N2510/00 ,  C12N2513/00 ,  C12N2533/50 ,  C12N2533/54

Abstract: Microfluidic devices for modeling three-dimensional tissue structures and methods for making and using the same are described herein.

公开(公告)号：US12129485B2

公开(公告)日：2024-10-29

申请号：US17057973

申请日：2019-05-23

Applicant: National University of Singapore

Inventor： Dario Campana ,  Natasha Vinanica ,  Yi Tian Png ,  Takahiro Kamiya

IPC: A61K48/00 ,  A61K35/17 ,  C07H21/04 ,  C07K14/705 ,  C07K14/725 ,  C07K16/28 ,  C12N5/0783 ,  C12N15/63 ,  A01K67/00

CPC classification number: C12N5/0636 ,  A61K35/17 ,  C07K14/70507 ,  C07K14/7051 ,  C07K14/70578 ,  C07K16/2806 ,  C12N5/0646 ,  C07K2317/622 ,  C07K2319/03 ,  C07K2319/04 ,  C12N2510/00

Abstract: The present invention provides engineered immune cells comprising an anti-CD2 protein expression blocker (PEBL) and an anti-CD2 chimeric antigen receptor (CAR). In some embodiments, such engineered immune cells lack surface expression CD2. Also, provided herein are methods of using such cells in cancer therapies.

公开(公告)号：US20240352470A1

公开(公告)日：2024-10-24

申请号：US18612750

申请日：2024-03-21

Applicant: THE TELOMERASE COMPANY, LLC

Inventor： Jason Ryan Steinbrunn

IPC: C12N15/74 ,  A61K35/747 ,  C12N1/20 ,  C12N9/12

CPC classification number: C12N15/746 ,  A61K35/747 ,  C12N1/205 ,  C12N9/1276 ,  C12N2510/00 ,  C12Y207/07049

Abstract: A composition that comprises recombinant probiotic organisms recombinantly engineered to constitutively express an enzyme involved in maintaining the length of telomeres, wherein the enzyme comprises telomerase subunits, the genetic modification comprises an operon that includes a promoter recognized by the probiotic organism's RNA polymerase and a gene sequence encoding telomerase with genetic modifications that induces secretion of telomerase into a host organism, and the genetic modification of the telomerase gene sequence enhances the telomerase enzyme entrance into the host organism's cells.

公开(公告)号：US20240352402A1

公开(公告)日：2024-10-24

申请号：US18443858

申请日：2024-02-16

Applicant: Wisconsin Alumni Research Foundation

Inventor： Helen Elizabeth Blackwell ,  Danielle Lee Widner

IPC: C12N1/20 ,  C12N15/75 ,  C12R1/125

CPC classification number: C12N1/205 ,  C12N15/75 ,  C12N2510/00 ,  C12R2001/125

Abstract: Described herein are engineered bacterial cells capable of producing an autoinducing peptide (AIP) or non-native AIP analog (including AIP inhibitors), methods for producing the AIP or non-native AIP analog, plasmids and kits. The bacterial cells are transformed with at least one plasmid into gram-positive bacterial cells expressing a mutation in the argD gene manipulating the AIP biosynthesis system via the AgrB/D to produce inhibitors of the S. aureus arg quorum sensing.

公开(公告)号：US20240343767A1

公开(公告)日：2024-10-17

申请号：US18683374

申请日：2021-12-27

Applicant: SHANGHAI SINOBAY BIOTECHNOLOGY CO., LTD.

Inventor： Jianqing Xu ,  Xiaoyan Zhang ,  Qibin Liao ,  Xiangqing Ding

IPC: C07K14/47 ,  A61K35/17 ,  A61K38/00 ,  A61P35/00 ,  C07K14/52 ,  C12N5/0783 ,  C12N15/67 ,  C12N15/86

CPC classification number: C07K14/4702 ,  A61K35/17 ,  A61P35/00 ,  C07K14/521 ,  C12N5/0636 ,  C12N15/67 ,  C12N15/86 ,  A61K38/00 ,  C12N2510/00 ,  C12N2740/15043 ,  C12N2830/002

Abstract: The present invention provides a hypoxia-triggered artificial transcription factor (HATF), and further provides a hypoxia-triggered transcription control system. The transcription control system comprises a nucleic acid sequence encoding the HATF, and a recognition element (RE). The hypoxia-triggered transcription control system comprises two sets of transcription control units linked upstream and downstream, wherein the upstream transcription control unit comprises a hypoxia-triggered transcription reaction element for controlling the HATF and a nucleic acid sequence encoding the HATF, and the downstream transcription control unit comprises an RE and a gene of interest. Co-regulation by the artificial transcription factor HATF and the recognition element RE can increase the expression of the gene of interest by a factor of one hundred.

公开(公告)号：US12115189B2

公开(公告)日：2024-10-15

申请号：US15746212

申请日：2016-07-21

Applicant: City of Hope

Inventor： Christine E. Brown ,  Stephen J. Forman

IPC: A61K35/17 ,  A61K39/00 ,  A61P35/00 ,  C07K14/705 ,  C07K14/725 ,  C07K16/28 ,  C12N5/0783 ,  C12N15/86

CPC classification number: A61K35/17 ,  A61K39/001112 ,  A61K39/001119 ,  A61P35/00 ,  C07K16/2803 ,  C07K16/2866 ,  C12N5/0636 ,  C12N15/86 ,  A61K2039/5156 ,  A61K2039/5158 ,  C07K14/7051 ,  C07K14/70521 ,  C07K2317/622 ,  C07K2319/03 ,  C07K2319/33 ,  C12N2501/2302 ,  C12N2501/2315 ,  C12N2510/00

Abstract: Methods for preparing T cell populations useful for a variety of purposes requiring a highly active, long-lived T cell population. The T cell populations are enriched for: naive T cells (TN), memory stem cells (TSCM) and central memory T cells (TCM). These cell populations can be derived from peripheral blood mononuclear cells (PBMC) by both: 1) depleting unwanted cell populations such as CD14 expressing myeloid cells and CD25 expressing cells; and 2) enriching for CD62L expressing memory and naive T cells.

公开(公告)号：US12110500B2

公开(公告)日：2024-10-08

申请号：US17993667

申请日：2022-11-23

Applicant: President and Fellows of Harvard College

Inventor： Torsten B. Meissner ,  Leonardo M. R. Ferreira ,  Jack L. Strominger ,  Chad A. Cowan

IPC: C12N5/0735 ,  A61K39/00 ,  C12N5/074 ,  C12N15/86 ,  C12N15/90

CPC classification number: C12N5/0606 ,  A61K39/001 ,  C12N5/0696 ,  C12N15/86 ,  C12N15/907 ,  C12N2310/20 ,  C12N2501/50 ,  C12N2501/599 ,  C12N2501/998 ,  C12N2510/00

Abstract: Disclosed herein are universal donor stem cells and related methods of their use and production. The universal donor stem cells disclosed herein are useful for overcoming the immune rejection in cell-based transplantation therapies. In certain embodiments, the universal donor stem cells disclosed herein do not express one or more MHC-I and MHC-II human leukocyte antigens. Similarly, in certain embodiments, the universal donor stem cells disclosed herein do not express one or more human leukocyte antigens (e.g., HLA-A, HLA-B and/or HLA-C) corresponding to MHC-I and MHC-II human leukocyte antigens, thereby rendering such cells hypoimmunogenic.

公开(公告)号：US20240327780A1

公开(公告)日：2024-10-03

申请号：US18622394

申请日：2024-03-29

Applicant: The Board of Trustees of the University of Illinois

Inventor： Angad P. Mehta ,  Marya Y. Ornelas ,  Angela Y. Thomas

IPC: C12N1/18 ,  A61K39/215 ,  C12N7/00 ,  C12N9/10 ,  C12N9/12 ,  C12N9/18

CPC classification number: C12N1/185 ,  A61K39/215 ,  C12N7/00 ,  C12N9/1007 ,  C12N9/1241 ,  C12N9/18 ,  C12N2510/00 ,  C12N2710/24122 ,  C12N2770/20022 ,  C12N2770/24122 ,  C12Y207/0705 ,  C12Y301/03033

Abstract: The emergence of zoonotic pathogenic viruses has accentuated the need to develop broad-spectrum antivirals and vaccines. Highly modular yeast-based phenotypic platforms for characterization and targeting of RNA capping enzymes from emerging pathogens including coronaviruses, MPV, ASFV, and WNV, are disclosed herein. This platform can identify key amino acid residues and protein domains. Inactivation and attenuation mutations in viral enzymes are also disclosed herein. This platform is applied to vertebrate RNA capping enzymes, demonstrating use for high-throughput phenotypic screening. The disclosed platforms are highly modular and can be adapted for RNA capping enzymes from viruses and variants that emerge in the future.

公开(公告)号：US20240327521A1

公开(公告)日：2024-10-03

申请号：US18293330

申请日：2022-07-27

Applicant: Seattle Children's Hospital d/b/a Seattle Children's Research Institute

Inventor： Michael C. Jensen ,  James Rosser

IPC: C07K16/28 ,  A61K39/00 ,  C07K14/55 ,  C07K14/705 ,  C07K14/725 ,  C12N5/0783

CPC classification number: C07K16/2827 ,  A61K39/4611 ,  A61K39/4631 ,  A61K39/464411 ,  A61K39/464412 ,  C07K14/55 ,  C07K14/7051 ,  C07K14/70521 ,  C07K14/70578 ,  C07K16/2803 ,  C12N5/0636 ,  A61K2239/15 ,  A61K2239/17 ,  A61K2239/22 ,  C07K2317/53 ,  C07K2317/622 ,  C07K2319/03 ,  C12N2510/00

Abstract: Some embodiments of the methods and compositions provided herein include methods and/or systems for increasing an activity of a cell comprising a chimeric antigen receptor (CAR), comprising use of a first nucleic acid encoding a transcription response element (TRE); and a second nucleic acid encoding a CAR, wherein the activity of the cell is increased compared to a cell lacking the first nucleic acid. In some embodiments, the increased activity of the cell is selected from: (i) survival of a subject administered the cell, wherein the subject comprises a target cell comprising an antigen, wherein the CAR is capable of specifically binding to the antigen; (ii) killing of a target cell comprising an antigen, wherein the CAR is capable of specifically binding to the antigen; and (iii) proliferation of the cell in the presence of a target cell comprising an antigen, wherein the CAR is capable of specifically binding to the antigen.